We recently compiled a list of the 35 AI Superstars According to Goldman Sachs. In this article, we are going to take a look ...
MT Newswires on MSN2d
Update On TSX Closer: BMO Capital Markets Adjusting Its S&P/TSX Price Target by 4% to 25,500 from 24,500The S&P/TSX Composite Index closed up 194.33 points to 24,162.83, having earlier posted an all time intraday high of 24,179.28, topping the previous high of 24.033.99 set on ...
BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...
BMO Capital analyst James Thalacker recently raised the price target on the stock to $90 from $88 and kept a Market Perform rating on the shares. The analyst cited the company’s positive ...
In a report released yesterday, James Thalacker from BMO Capital reiterated a Buy rating on Vistra Energy (VST – Research Report), with a price target of $146.00. The company’s shares closed ...
The S&P 500 index recorded impressive gains of 20% so far in 2024 to hit a level of around 5,740 points as of this writing, ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.35% of ...
On Friday, BMO Capital maintained its Outperform rating on Goeasy Ltd (GSY:CN) (OTC: EHMEF) with a steady price target of Cdn$218.00. The firm anticipates a slight increase in credit losses for ...
Bond-market participants are looking beyond U.S. economic data right now and considering geopolitical developments as part of the thinking behind their trades, according to strategists at BMO Capital ...
BMO Capital analyst Thanos Moschopoulos thinks the potential actions of Lightspeed could unlock some value for shareholders.
BMO Capital Markets has maintained its positive stance on Vistra Energy (NYSE: NYSE:VST), increasing the stock's price target to $146 from the previous $125 while reiterating an Outperform rating.
On Friday, BMO Capital maintained its optimistic stance on Prime Medicine (NASDAQ:PRME), reiterating an Outperform rating with a price target of $19.00. The firm highlighted the biotechnology ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback